Media coverage about Spero Therapeutics (NASDAQ:SPRO) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spero Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.8816789399444 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Spero Therapeutics (NASDAQ:SPRO) traded up $0.08 during trading on Tuesday, reaching $10.04. The company had a trading volume of 24,200 shares, compared to its average volume of 25,863. Spero Therapeutics has a 1 year low of $9.66 and a 1 year high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.43) by ($33.59). The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $0.20 million. equities analysts anticipate that Spero Therapeutics will post -8.52 EPS for the current year.

A number of analysts have recently issued reports on the company. Zacks Investment Research lowered Spero Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 11th. ValuEngine raised Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Cantor Fitzgerald began coverage on Spero Therapeutics in a report on Thursday, February 8th. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, Cowen began coverage on Spero Therapeutics in a report on Monday, November 27th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Spero Therapeutics has an average rating of “Hold” and an average target price of $24.25.

ILLEGAL ACTIVITY WARNING: “Spero Therapeutics (SPRO) Receiving Somewhat Favorable News Coverage, Report Shows” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Insider Buying and Selling by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with's FREE daily email newsletter.